RVL Pharmaceuticals PLC

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL”), the owner of UPNEEQ®, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis (low-lying lids) in adults.

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Brian Markison - CEO Mike DePetris - Interim CFO JD Schaub - COO Conference Call Participants Louise Chen - Cantor Douglas Tsao - H.C Wainwright Michaela Diverio - Barclays Operator Good day and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2022 Earnings Call.

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q2 2022 Results - Earnings Call Transcript

-- Second quarter 2022 UPNEEQ ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings --

RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update

-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closing and an additional $25.0 million of availability through April 2023, subject to a minimum revenue target --

RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing

Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET

RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update

Clean Energy Fuels

DigitalBridge Group

GSI Technology

NeoPhotonics

TripAdvisor

Wolfspeed

Not all stocks will benefit even if the markets turn around. These stocks to sell are likely to keep going lower, rather than rebounding.

7 Stocks to Sell Now

--  Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- --  Second quarter 2022 net product sales growth contributes to approximately $14.4 million in the six months ended June 30, 2022 -- --  Expects approximately 2,200 cumulative unique medical aesthetics practices placed orders for UPNEEQ through quarter-end -- --  Reaffirms fourth quarter 2022 UPNEEQ net product sales guidance of $20 to $25 million -- BRIDGEWATER, N.J. , July 7, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced preliminary second quarter 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration ("FDA")-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of $8.4 million.

RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results

BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company's Annual General Meeting.

RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

RVL Pharmaceuticals plc to Present at Upcoming Conferences

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer Mike DePetris – Interim Chief Financial Officer JD Schaub – Chief Operational Officer Conference Call Participants Douglas Tsao – H.C Wainwright Louise Chen – Cantor Greg Fraser – Truist Securities Balaji Prasad – Barclays Operator Good morning everyone. My name is Bertney and I will be your conference operator.

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q1 2022 Results - Earnings Call Transcript

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 48% and 197.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) Reports Q1 Loss, Tops Revenue Estimates

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

BRIDGEWATER, N.J. , May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has received another industry award.

UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"

Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET

RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update

12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquired blepharoptosis (ptosis) drug UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a "Best  in Innovation" award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication.

UPNEEQ® Wins "Best in Innovation" Award from New Beauty

-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidance of $20 to 25 million in UPNEEQ net product sales --

RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q4 2021 Results - Earnings Call Transcript

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates

Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business Update

Hapless Osmotica renamed itself RVL Pharmaceuticals. It has a novel business model which vastly simplifies its business. Encouragingly, recent company estimate pegs 2022 Q4 UPNEEQ net revenues at $20-$25 million.

RVL Pharmaceuticals - A Makeover For An Ugly Duckling

-- Conference call to be held March 30, 2022, at 4:30 p.m. ET -- -- Conference call to be held March 30, 2022, at 4:30 p.m. ET --

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch

BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022, as follows:

News for RVL Pharmaceuticals PLC Stock (RVLP)